JPM
JPMorgan Chase & Co.
JPM has a slight edge over XRN overall, supported by stronger modeled upside and stronger fundamentals.
XRN
Chiron Real Estate Inc.
XRN offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
XRN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| N/A | |
| N/A |
XRN's profitability is currently healthy, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like XRN.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM's PE is in its expensive range at 14.4x. If earnings grow as analysts expect, today's price would be 13.7x next year's earnings.
XRN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 7.6x | $26.58 | — |
| Cheap | 36x | $127 | +378% |
| Fair | 50x | $173 | +550% |
| Expensive | 109x | $381 | +1335% |
Historical ranges are pointers, not guarantees.
XRN has the edge over JPM in the historical PE scenario, which offers more potential upside but is not a forecast.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
JPM has the edge over XRN on the outlook, with more favorable earnings and revenue expectations.
XRN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect XRN's losses to grow, with revenue declining.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM has the edge over XRN on earnings, with more consistent year-over-year improvement.
XRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $3.49 | +$3.74 |
| Q2 2026 | $3.71 | +960% |
| Q1 2026 | -$1.12 | -847% |
| Q4 2025 | -$0.91 | -1920% |
| Q3 2025 | -$0.25 | -$0.15 |
| Q2 2025 | $0.35 | +$0.35 |
| Q1 2025 | $0.15 | -87% |
| Q4 2024 | $0.05 | -96% |
XRN has returned to profit: it earned $3.49 per share over the past year, after losing money the year before.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM's revenue has grown year over year for five quarters in a row: $50.2B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM's operating margin was 40% last quarter, about level with the same quarter a year ago.
XRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $40.3M | +8.3% |
| Q2 2026 | $39.7M | +4.7% |
| Q1 2026 | $38.1M | +10% |
| Q4 2025 | $38.4M | +9.2% |
| Q3 2025 | $37.2M | +8.7% |
| Q2 2025 | $38M | +11% |
| Q1 2025 | $34.6M | -1.4% |
| Q4 2024 | $35.2M | +6.7% |
XRN's revenue has grown year over year for six quarters in a row: $40M last quarter, up 8.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 65% | N/A |
| Q2 2026 | 75% | N/A |
XRN has the edge over JPM on profitability, with a higher operating margin.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
XRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.3M | -53% |
| Q2 2026 | $19.5M | -12% |
| Q1 2026 | $11.2M | -8.7% |
| Q4 2025 | $21.6M | +5.4% |
| Q3 2025 | $17.6M | +7.8% |
| Q2 2025 | $22.1M | +17% |
| Q1 2025 | $12.3M | -14% |
| Q4 2024 | $20.5M | +13% |
XRN has the edge over JPM on cash generation, producing positive trailing cash flow while its opponent burns cash.
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has the edge over XRN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
XRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +5K shares |
| 1 year | -1.1% | -153K shares |
| 3 years | +1% | +127K shares |
| 5 years | +3.1% | +399K shares |
| Available history | +75% | +5.7M shares |
XRN has 13M diluted shares, down 1.1% from a year ago.
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like JPM.
XRN Net Leverage
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
XRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.3 | Oversold |
| Stochastic | 10.9 | Oversold |
XRN's weekly RSI is 25 (oversold) and its Stochastic is 11 (oversold).
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM is trading at 14x earnings, a 10% premium to the Financial Services sector's median of 13x.
XRN PE vs Financial Services Sector
| Metric | XRN | Sector median | Relative |
|---|---|---|---|
| PE | 7.6x | 13x | 41% below |
| PE % | 0 | 63 | 63 pts below |
XRN has the edge over JPM on valuation relative to its sector.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM has the edge over XRN on trend strength, trading above more of its moving averages.
XRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 15% below |
| 20 week MA | $34.5 | 23% below |
| 50 week MA | $34.8 | 24% below |
| 100 week MA | $35.5 | 25% below |
| 200 week MA | $41.3 | 36% below |
XRN is in a downtrend: it's below all five of its weekly moving averages, and 36% below its 200-week average.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has the edge over XRN on returns for 2026, with the stronger performance.
XRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $64.6 | $67.0 | +3.7% |
| 2021 | $67.0 | $85.8 | +28% |
| 2022 | $85.8 | $46.9 | -45% |
| 2023 | $46.9 | $55.5 | +18% |
| 2024 | $55.5 | $38.1 | -31% |
| 2025 | $38.1 | $33.5 | -12% |
| 2026 YTD | $33.5 | $26.6 | -21% |
XRN has finished lower in three of the last six years. It's down 21% so far in 2026.